Genetic causes of mitochondrial DNA depletion in humans  by Rötig, Agnès & Poulton, Joanna
Biochimica et Biophysica Acta 1792 (2009) 1103–1108
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbad isReview
Genetic causes of mitochondrial DNA depletion in humans
Agnès Rötig a,⁎, Joanna Poulton b
a INSERM U781, Hôpital Necker-Enfants Malades, Université René Descartes Paris V, 149 rue de Sèvres, 75015 Paris, France
b Nufﬁeld Department of Obstetrics & Gynaecology, University of Oxford, The Womens Centre, John Radcliffe Hospital, Oxford, OX3 9DU, UK⁎ Corresponding author.
E-mail addresses: agnes.rotig@inserm.fr (A. Rötig),
Joanna.poulton@obs-gyn.ox.ac.uk (J. Poulton).
URL: http://www.obs-gyn.ox.ac.uk/research/Poulto
0925-4439/$ – see front matter © 2009 Published by E
doi:10.1016/j.bbadis.2009.06.009a b s t r a c ta r t i c l e i n f oArticle history:
Received 7 January 2009
Received in revised form 19 June 2009
Accepted 24 June 2009
Available online 9 July 2009
Keywords:
Mitochondria
mtDNA depletion
Respiratory chainMitochondrial DNA (mtDNA) depletion is characterized by a profound reduction of mtDNA copy number. The
maintenance ofmtDNAcopynumber requires several nuclear-encoded factors involved in replication and indNTP
supply. In the past decade mutations in several of these factors have been reported in a growing number of
syndromes. This article reviews the current knowledge of genes causingmitochondrial DNAdepletion syndromes.
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Mutations in either mitochondrial DNA (mtDNA) or nuclear genes
that encode proteins involved in various functions, including mtDNA
maintenance may cause mitochondrial disease. Pathological altera-
tions of mtDNA fall into three major classes: point mutations,
deletion-duplications and disordered mtDNA content, that is, copy
number. Reduction of mtDNA copy number to less than 30% of normal
mtDNA content is deﬁned as mtDNA depletion, which causes a
heterogeneous group of severe and usually lethal diseases in infancy
and childhood. While genetic causes are the focus of this review,
mtDNA depletion can also be drug-induced [1]. Mitochondrial DNA
depletion syndrome (MDS) was ﬁrst described as congenital myo-
pathy or hepatopathy [2]. Since then, many patients have been
reported with different clinical presentations such as hepatocerebral,
myopathic and encephalomyopathic forms. In these patients, there is
a marked (usually tissue speciﬁc) deﬁciency in mtDNA level. MtDNA
encodes proteins of respiratory chain (RC) complexes I, III, IV and V.
Hence, mtDNA depletion results in deﬁciencies of multiple RC
complexes, while nuclear-encoded components such as complex II
are expressed normally. Nevertheless, the precise RC defect may vary
considerably, and an isolated deﬁciency in a single complex may be
apparent. The recurrence of the disease in some families and the
consanguinity of parents in others demonstrate that MDS is inherited
in an autosomal recessive pattern, with a primary nuclear gene defect
causing secondary mtDNA loss. Several gene mutations are known to
result in mtDNA depletion and most of them are involved directly orn (J. Poulton).
lsevier B.V.indirectly in mtDNA replication or in replenishing the mitochondrial
deoxyribonucleoside triphosphate (dNTP) pool for mtDNA synthesis.
Maintenance and integrity of themitochondrial genome depend on
several poorly understood factors. mtDNA is packaged into protein–
DNA complexes called nucleoids. Nucleoids in cultured mammalian
cells contain 5–10mtDNAmolecules [3,4] and appear to be tethered to
the inner mitochondrial membrane. The protein composition of the
nucleoid is still controversial, nevertheless it is now well established
that the nucleoid contains the mtDNA replisome. Crucial proteins or
enzymes involved in either mtDNA replication (mtDNA polymerase γ,
mtSSB, Twinkle helicase) or transcription (TFAM) are components of
the nucleoid [3]. Theoretically, defects in any of the proteins involved
in mtDNA replication might affect mtDNA copy number. MtDNA
replication is also highly dependent on mitochondrial dNTPs supply,
and mutations in several genes involved in mitochondrial dNTP
synthesis may therefore cause MDS.
2. Incidence of mtDNA depletion
MtDNA depletion is a rare cause of mitochondrial disease, which is
itself rare. There are no published prevalence studies of MDS. Based on
the Necker Hospital series of patients, roughly 8% of pediatric patients
with respiratory chain deﬁciency present with mtDNA depletion.
Patients with POLG1 mutations comprise the largest single group of
individuals with MDS, and in Oxford this is one of the commonest
distinct types of pediatric mitochondrial myopathy. The prevalence of
Alpers-Huttenlocher syndrome, the major POLG1 phenotype, is held
to be around 1 in 100,000 [5].
3. MDS and abnormal mitochondrial nucleotide salvage
MtDNA replication occurs throughout the whole cell cycle,
depending on speciﬁc intramitochondrial 2′-deoxyribonucleoside 5′-
Table 1
Nuclear gene mutations responsible of mtDNA depletion.
Gene Protein Depleted
tissue
Clinical
presentation
Pathway
TK2 TK2 Muscle Myopathy Mitochondrial dNTP
synthesisDGUOK dGK Liver Hepatocerebral
form
SUCLA2 SCS Muscle Encephalomyopathy
SUCLG1 SCS Muscle and
Liver
Fatal infantile lactic
acidosis
POLG1 POLG Liver Alpers-Huttenlocher
syndrome,
hepatocerebral form
mtDNA replication
PEO1 Twinkle Muscle PEO
RRM2B p53R2 Muscle Encepahlopathy Cytosolic dNTP
synthesisTYMP Thymidine
phosphorylase
Muscle MNGIE
1104 A. Rötig, J. Poulton / Biochimica et Biophysica Acta 1792 (2009) 1103–1108triphosphate (dNTP) pools [6]. Because mtDNA turns over in post
mitotic cells [7], it is clear that mtDNA is able to replicate in the
absence of normal cell cycling, but it may not be completely
autonomous [8]. A constant supply of dNTP is therefore required for
mtDNA replication. The synthesis of dNTPs for mtDNA replication is
not completely elucidated. There is no de novo dNTP synthesis in
mitochondria. Nucleotides are either imported from the cytosol or
result from the mitochondrial salvage pathway. Cytosolic dNTPs are
predominantly synthesized de novo by the ribonucleotide reductase
(RNR). RNR is S-phase speciﬁc and therefore the cytosolic de novo
synthesis cannot provide all required dNTPs for mtDNA replication in
quiescent cells and non-dividing tissues. dNTPs are also synthesized
via the cytosolic salvage pathway (Fig. 1). These dNTPs are imported
into the mitochondria by speciﬁc transporters [9,10].
The mitochondrial salvage pathway (Fig. 1) involves speciﬁc
mitochondrial enzymes. Firstly deoxyribonucleosides are phosphory-
lated by deoxyribonucleoside kinases (dNK). This is followed by two
further phosphorylation steps, ﬁrstly involving nucleotide monopho-
sphate kinase (NMPK) and secondly nucleotide diphosphate kinase
(NDPK). The two major dNKs are deoxyguanosine kinase (dGK) and
thymidine kinase (TK), encoded by DGUOK and TK2 genes respec-
tively. In non replicating tissues, cytosolic deoxyribonucleotides levels
are low and mitochondrial dNTP salvage is the major source of
nucleotides. Mutations in the mitochondrial dNTP salvage pathway
have been reported in different forms of MDS.
3.1. DGUOK mutations in hepatocerebral form of MDS
Mitochondrial DNA depletion of liver is the most common form of
MDS, patients falling into two major phenotypes, the so-called
hepatocerebral form and Alpers-Huttenlocher syndrome (see
below). Homozygosity mapping in three different consanguineous
families of Druze origin identiﬁed chromosome 2p13 as the ﬁrst
hepatocerebral MDS disease locus. Candidate genes were sequenced
and DGUOKwas identiﬁed as the disease causing gene [11]. Since then,
over 50 patients have been reported with DGUOKmutations (Table 1).
The clinical presentation of the patients was relatively similar. Onset
of the disease is in early infancy with neonatal or delayed forms (1 to
24 months). The initial symptoms are liver dysfunction, feedingFig. 1. dNTP synthesis fodifﬁculties, hypotonia and/or hypoglycemia. All patients manifested
hyperlactatemia. Characteristically, such patients develop microvesi-
cular steatosis in liver, with hepatocellular insufﬁciency progressing to
liver failure. Patients usually die before reaching 2 years old [12].
Diagnosing such patients may be difﬁcult unless liver is available for
analysis, and such patients are frequently too sick to biopsy [13].
Enzymological measurement of the liver RC revealed combined
deﬁciency of mtDNA-encoded complexes. The mtDNA content is
usually reduced to less than 10% of normal copy number in liver of the
patients and may be reduced in ﬁbroblasts [14], whereas muscle
mtDNA content is usually within the normal range.
3.2. TK2 mutations in myopathic form of MDS
TK2 was also an obvious candidate gene for MDS because its
function is similar to that of DGUOK. Analysis of this gene revealed two
missense mutations in four patients with isolated myopathy and
muscle mtDNA depletion [15]. The mutation was shown to be
pathogenic because TK2 activity was decreased in muscle mitochon-
dria (Table 1). TK2 mutations were then described in additional
myopathic patients [16] but the phenotypic spectrum of TK2
mutations turned out to be more complex than a simple myopathy.r mtDNA synthesis.
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spinal muscular atrophy and encephalopathy were found to have TK2
mutations [17]. Very recently, Finnish TK2 patients were also reported,
presenting with seizures, cardiomyopathy or dystrophic changes in
muscle [18]. Secondly, depletion of mtDNA at presentation may
become less apparent as the disease progresses, despite clinical and
biochemical deterioration [16]. The mechanism behind the increase in
mtDNA copy number in this and other patients with a similar
molecular progression [14,19] remains unexplained.
3.3. Succinyl CoA synthase deﬁciency
Succinyl CoA synthase (SCS) is amitochondrial matrix enzyme that
catalyzes the reversible synthesis of succinate and ATP (or GTP) from
succinyl-CoA and ADP in the tricarboxylic acid (TCA) cycle. This
enzyme is composed of anα-subunit (SCS-G) and a β-subunit (SCS-A),
encoded by the SUCLG1 and SUCLA2 genes respectively. By homo-
zygosity mapping in a small consanguineous pedigree with autosomal
recessive encephalomyopathy and mtDNA depletion, Elpeleg's group
identiﬁed a homozygous deletion of exon 6 and part of exon 7 of
SUCLA2 gene [20]. The patients presented psychomotor retardation,
muscle hypotonia, hearing impairment and seizures (Table 1). Brain
MRI suggested Leigh syndrome. A deﬁciency of multiple RC complexes
was observed in muscle and the mtDNA content was reduced to 32% of
the mean value. Following this initial report, SUCLA2 mutations were
found in several patients from the remote Faroe Islands presenting
encephalomyopathy, muscle mtDNA depletion, and methylmalonic
aciduria [21]. The high incidence of this disorder in the Faroe Islands
(1/1700) is due to a founder effect, with a carrier frequency of 1 in 33.
SUCLA2 mutations were then also reported in Italian patients with
methylmalonic aciduria [22]. Mutations in SUCLG1 encoding the SCS
α-subunit were also reported in patients with fatal infantile lactic
acidosis, multiple RC deﬁciency and a decreased amount of mtDNA
(15% of normal) [23]. The mutation, a 2 bp deletion, resulted in a frame
shift and a premature stop codon. A useful diagnostic clue in both of
these subtypes is a mildly elevated urinary methylmalonic acid.
The pathogenesis of this disorder is poorly understood. It is not
clear how the enzyme deﬁciency results in mtDNA depletion and RC
deﬁciency. Under some conditions SCS-A copuriﬁes with the nucleo-
side diphosphate kinase (NDPK) that catalyzes the last step of
mitochondrial dNTP salvage [24]. Thus it could be that SCS deﬁciency,
due to SUCLA2 or SUCLG1 mutations, disrupts an association between
SCS and NDPK, resulting in an unbalanced mitochondrial dNTP pool
and eventually mtDNA depletion. Moreover, the mtDNA depletion is
frequently mild in muscle. The modesty of this depletion, along with
the methylmalonic aciduria, suggests that SCS deﬁciency may also
impair at least one collateral pathway that plays a role in the
development of the disease.
4. MDS and cytosolic deoxynucleotide metabolism
The mitochondrial dNTP pool is highly dependent on cytosolic
dNTPs and an unbalanced cytosolic dNTP pool can be genotoxic for
mtDNA.
The ﬁrst reported example of mitochondrial disease related to
defective cytosolic dNTP pool is mitochondrial neurogastrointestinal
encephalomyopathy (MNGIE). MNGIE is characterized clinically by
ptosis, progressive external ophthalmoplegia (PEO), gastrointestinal
dysmotility, peripheral neuropathy, myopathy, leukoencephalopathy
and lactic acidosis. Patients may present with some or all of these
features, quite frequently as a progressive generalized mixed motor
and sensory neuropathy [25]. In most cases, the onset of symptomatic
disease is between the second to ﬁfth decades, but many patients will
always have been underweight. Patients present with decreased RC
activities inmuscle andmultiple mtDNA deletion ormtDNA depletion,
or both (Table 1). The disease is autosomal recessive and by linkageanalysis and sequencing candidate genes, Hirano's group demon-
strated that it was caused by mutations in the thymidine phosphor-
ylase (TYMP) gene [26]. Thymidine phosphorylase is a catabolic
enzyme that degrades thymidine and deoxyuridine and participates in
the regulation of thymidine phosphate pools (Fig. 1). Interestingly
thymidine phosphorylase is a cytosolic enzyme and is not directly
involved in mitochondrial dNTP pool regulation. Because MNGIE
patients have elevated circulating and urinary thymidine and uridine
levels [27], many investigators suggest that thymidine toxicity is the
cause of the phenotype. Nevertheless, there is evidence that most of
the ﬁltered thymidine is likely to be reabsorbed by the kidney which
should therefore worsen the phenotype [28]. Furthermore, renal
dialysis was not helpful, suggesting that the problem might be
imbalance in mitochondrial dNTP pools [28,29] rather than thymidine
excess [14]. The study of intramitochondrial dNTP levels in cells from
patients withMNGIE directly is technically difﬁcult as crudely puriﬁed
preparations of mitochondria are substantially contaminated with
nuclear or cytoplasmic dTTP. Nevertheless, it is clear that nucleotide
imbalance may be mutagenic, because as little as 4 hours of treatment
of HeLA cells with thymidine supplements induced an increase of
mitochondrial dTTP and dGTP pools, and multiple mtDNA deletions
were apparent after 8 months of culture [30]. Finally, the thymidine
phosphorylase (TYMP) and uridine phosphorylase (UP) double
knockout (TYMP−/−UP−/−) mice manifested increased thymidine
and deoxyuridine in various tissues and altered mitochondrial dNTP
pools [31]. They also displayedmtDNA depletion and respiratory chain
dysfunction in brain recapitulating some features of patients with
MNGIE.
Ribonucleotide reductase (RNR) is a cytosolic enzyme that
catalyzes dNDP synthesis from NDP [32]. This is the rate limiting
step for nuclear DNA synthesis. This ribonucleotide reductase consists
of one homodimer of the large subunit R1 and one homodimer of the
small subunit R2. The large subunit R1 is constitutively expressed
whereas R2 gene is transcribed only during S-phase and R2 protein is
destroyed in late mitosis. Thus, this R1–R2 complex is essential for
dNDP synthesis for nuclear DNA replication during S-phase. However,
dNTP synthesis is essential during other phases of the cell cycle for
both DNA repair (after DNA damage) and for mtDNA replication.
Another small subunit (p53R2 encoded by RRM2B gene) was
identiﬁed in 2000 that is 80% identical with R2 and whose expression
is cell-cycle independent [33]. RRM2B is a target of the p53
transcription factor which is induced by DNA damage, the R1–p53R2
complex possibly enabling dNDP synthesis for DNA repair after DNA
damage. It is now clear that p53R2 plays an additional role in
supplying dNTPs for mtDNA replication [34] as genetic mapping in a
small North-African pedigree with profoundmuscle mtDNA depletion
(1–2% of normal mtDNA content) demonstrated that RRM2B was the
disease gene [35]. The ﬁrst patients in whom RRM2B mutations were
identiﬁed presented early with severe trunk hypotonia and lactic
acidosis, as well as proximal tubulopathy (Table 1). Less severe clinical
presentations were later reported [36]. This shows that p53R2 plays a
crucial role in dNTP synthesis for mtDNA replication, especially in
non-proliferating tissues such as muscle and brain.
5. MDS and mtDNA replication
mtDNA is replicated by the DNA polymerase γ (pol γA), encoded
by the POLG1 gene and its accessory subunit (pol γB), encoded by the
POLG2 gene, and replication factors such as the mitochondrial single
strand DNA binding protein (mtSSB) and the Twinkle helicase
(encoded by PEO1). Diseases resulting from mutations in POLG and
PEO1 genes are associated with diverse disorders such as progressive
external ophthalmoplegia (PEO) [37], SANDO syndrome (Sensory
ataxia, neuropathy, dysarthria, ophthalmoparesis), MIRAS (mitochon-
drial-associated recessive ataxia syndrome) [38], IOSCA (infantile
onset spinocerebellar ataxia), Alpers-Huttenlocher syndrome [39] and
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genes can be inherited as autosomal dominant [37] or recessive traits
[38]. Patients present either qualitative (multiple deletions) [37] or
quantitative (depletion) mtDNA abnormalities [39].
Alpers-Huttenlocher syndrome is characterized by psychomotor
retardation, intractable epilepsy, and liver failure in infants and young
children. Nevertheless, patients may present with isolated neurolo-
gical or liver disease, most commonly convulsions. The clinical picture
overlaps with hepatocerebral syndrome [39–41]. Intractable epilepsy
and/or movement disorders are a major feature of Alpers-Huttenlocher
syndrome, continuous seizure activity (epilepsiapartialis continua) being
a frequent terminal event [42]. The outcome is universally poor, with
progressive neurological deterioration characterized by spasticity,
myoclonus, cortical blindness, and dementia. Patients with Alpers-
Huttenlocher syndrome usually, but not always, exhibit RC deﬁciency
andmtDNAdepletion in liver, but bothmay be normal in skeletalmuscle
[43]. Patients with the most severe phenotypes, manifesting as mtDNA
depletion in liver and muscle as well as mosaic mtDNA depletion in
ﬁbroblasts, have mutations in a catalytic domain in both POLG alleles.
These mutations may involve either the polymerase or exonuclease
domain or both [42]. More than 120 POLGmutations have been reported
to date (http://tools.niehs.nih.gov/polg/) andmany of thesemutations
may also cause PEO. The two most common POLG mutations found in
Alpers-Huttenlocher syndrome are A467T andW748S, and patients can
be homozygotes or compound heterozygotes combined with other
mutations (Table 1).
Mutations in PEO1 can cause dominant disorders such as pure
PEO associated with multiple mtDNA deletions or recessive disorders
including IOSCA syndrome or hepatocerebral form of MDS (Table 1).
IOSCA is a severe autosomal recessively inherited neurodegenerative
disorder characterized by progressive atrophy of the cerebellum,
brain stem and spinal cord and sensory axonal neuropathy. This
syndrome has been reported in Finnish patients and by genetic
mapping a recessive homozygous Y508C founder mutation in PEO1
gene has been found [44]. Surprisingly, RC and mtDNA copy number
were normal in muscle of the patients while autosomal dominant
PEO1 gene mutations result in multiple RC deﬁciency and multiple
mtDNA deletions in muscle. However, it has been recently shown
that IOSCA syndrome is associated with brain-speciﬁc mtDNA
depletion and complex I deﬁciency in tissue samples taken at autopsy
[45].
6. MPV17 mutations and hepatocerebral form of MDS
The hepatocerebral form of MDS is associated with not only
DGUOK or POLGmutations, but also with mutations in theMPV17 gene
(Table 1). Thesemutations have been identiﬁed by genetic mapping in
several unrelated consanguineous families of Italian, Canadian or
North-African origin [46]. The patients presented with severe
hypoglycemic episodes, jaundice and elevated levels of lactate and
hepatic enzymes in blood. Most of the patients died of liver failure
during the ﬁrst year of life. Patients who survived then developed
neurological symptoms and multiple brain lesions. All probands had
profoundmtDNA depletion (5–15% of normal mtDNA content) in liver
associated with defects of mtDNA-related respiratory chain com-
plexes. MPV17 mutations are also associated with Navajo neurohepa-
topathy, an autosomal recessive multisystem disorder prevalent in the
Navajo population of the southwestern United States [47]. Patients
present with liver disease, severe sensory and motor neuropathy,
corneal anesthesia and scarring, cerebral leukoencephalopathy, failure
to thrive, and recurrent metabolic acidosis with intercurrent illness.
They all carry the same R50Q founding mutation.
MPV17 encodes a protein of yet unknown function and its role in
the pathogenesis of mtDNA depletion is still unclear. In contrast to
previous reports suggesting that Mpv17 isoforms are localized in
peroxisomes [48] it has recently been shown that Mpv17 is actually amitochondrial protein bound to the inner mitochondrial membrane
[46].
7. Tissue speciﬁcity
Despite the ubiquitous expression of their gene products, the
mtDNA depletion arising from these mutant genes is frequently
restricted to speciﬁc tissues. For instance, the main tissue where
depletion is apparent is liver in patients with DGUOK, POLG,MPV17 or
PEO1mutations, andmuscle in patients with TK2 or RRM2Bmutations.
Nevertheless, the expression of these genes is different in various
organs and tissues as well as the expression of other genes involved in
the affectedmetabolic pathway. The tissue-speciﬁc regulation of these
genes, especially those involved in mitochondrial dNTP pools allows
some times to understand the tissue speciﬁcity of MDS.
TK2 deﬁciency results in muscle mtDNA depletion whereas other
tissues usually display normal mtDNA copy number. Several factors
could contribute to this tissue speciﬁcity. Firstly, the de novo
cytosolic dNTP synthesis by RNR is down regulated in non-dividing
tissues. Hence, the mitochondrial dNTP pool is strictly dependent on
the mitochondrial salvage pathway. TK2 deﬁciency should be
therefore highly detrimental in these tissues whereas dividing
tissues, such as liver, show normal mtDNA copy number. However,
brain and heart are also non-dividing tissues and some patients also
manifest cardiomyopathy and encephalopathy. A second reason is
that the mitochondrial dNTP pools are different among different
organs, at least in rat [49] and in mouse [10] and muscle dTTP
content being very low compared to dATP, dCTP and dGTP. Thus a
decreased dTTP synthesis due to TK2 deﬁciency can be much more
detrimental in muscle tissue than in other organs. Finally, basal TK2
activity is very low in human muscle tissue compared to liver or
heart and low TK2/COX and TK2/mtDNA ratios are observed in
muscle [50]. This could also contribute to the vulnerability of
skeletal muscle to TK2 deﬁciency.
The RRM2B gene is ubiquitously expressed in humans, with high
expression in skeletal muscle. In contrast, transcripts encoding R2 are
undetectable in heart, brain and muscle, implying that these tissues
rely entirely on p53R2 for dNTPs synthesis, whereas a low but
signiﬁcant amount of R2 is detected in kidney [51]. Why RRM2B
mutations resulted only in severe neurological and/or renal involve-
ment remains an open question. Other mechanisms, including post-
translational modiﬁcations of p53R2 or R2 or post-transcriptional
modiﬁcations of their respective mRNAs, could help explain the
tissue-speciﬁc phenotype of p53R2 mutations.
The tissue speciﬁcity associated with DGUOK, MPV17, POLG, PEO1,
SUCLA2 or SUCLG1 mutations is still not understood.
8. Animal models
Several mouse models with deﬁciencies in genes able to cause
human mtDNA depletion are now available and will constitute tools
for improving both the knowledge of the control of mtDNA copy
number and for identifying clues for treatment.
Both TK2 knock-in (H126N) and TK2−/− knockout mice have been
generated [52,53]. They were both normal at birth but rapidly
developed progressive weakness or growth retardation and died
before 4 weeks of age. They also manifested mtDNA depletion. The
knock-in mouse displayed unbalanced dNTP pools.
The RRM2B −/− mouse developed normally until they were
weaned but from then on had growth retardation and early mortality.
Theymanifestedmultiorgan failure and died of renal failure [54]. Even
though the role of p53R2 is to supply dNTP for DNA repair, there was
no evidence of any malignancy. However, a severe mtDNA depletion
was detected in muscle and kidney conﬁrming the role of p53R2 in
dNTP supply for mtDNA synthesis [35].
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retroviral construct in the genome of mouse embryonic stem cells
[55]. This mouse had severe mtDNA depletion restricted to liver but
moderate decrease of RC activities. Surprisingly the animals did not
develop overt hepatic failure at any age, but did develop grey hair
early in adulthood and focal segmental glomerulosclerosis with
massive proteinuria and cochlear lesions [56].
Although these various mouse models show clear alteration either
of the mitochondrial dNTP pools or decreased mtDNA copy number,
they do not always display RC deﬁciency suggesting compensatory
mechanisms. This compensation may occur at the level of mtDNA
transcription and possibly translation as shown for the MPV17−/−
mouse [56].
Mice with targeted deletion of both thymidine phosphorylase
and uridine phosphorylase genes develop leukoencephalopathy and
myopathy, but not the gastrointestinal features that are a hallmark of
MNGIE [31].
9. Therapeutic approaches
For the majority of patients with MDS, there is as yet no treatment
other than supportive care, even though this group of disorders is
potentially the most treatable of mitochondrial diseases [57]. Liver
transplantation is contraindicated in Alpers-Huttenlocher syndrome
because of the inevitable brain involvement that may not be apparent
until later. Furthermore, 6 out of 9 infants who underwent liver
transplantation for hepatocerebral syndrome due to DGUOK muta-
tions died [13]. Very few DGUOK patients responded well to liver
transplantation suggesting that which may be a therapeutic option in
selected cases [17].
This contrasts with the options available for patients with
thymidine phosphorylase deﬁciency (MNGIE) in whom there is
nucleotide imbalance with systemic accumulation of its substrates,
thymidine (dThd) and deoxyuridine (dUrd). While reducing the
concentrations of the allegedly toxic nucleosides to normal or nearly
normal levels by dialysis was ineffective, enzyme replacement by
infusion of platelets from healthy donors to patients with MNGIE
reduced plasma dThd and dUrd levels [58]. Concomitantly, reduced
intensity allogenic stem cell transplantation has been performed in
two patients that partially restored buffy coat thymidine phosphor-
ylase activity and lowered plasma nucleosides in one of them [59].
While it is not yet certain that such patients improve clinically, this is
nevertheless extremely encouraging, bone marrow transplant being
the ﬁrst potential cure for a mitochondrial disease.
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